Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3

Gossamer Bio, Inc.

Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.
TORREY open-label extension topline data expected mid-2023.
GB5121 Phase 1b/2 enrollment paused due to benefit/risk profile and resource prioritization toward seralutinib.
Cash of $255.7M at Dec 31, 2022; expected to fund operations into H2 2024.
Full-year 2022 net loss $229.4M ($2.71/share), vs $234.0M ($3.13/share) in 2021.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gossamer Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the full year ended December 31, 2022, was $229.4 million, EPS $2.71 per share.

Period: the full year ended December 31, 2022
Net income: Net loss for the full year ended December 31, 2022, was $229.4 million
EPS: $2.71 per share
Result: reported results

Exact text from the filing

Net loss for the full year ended December 31, 2022, was $229.4 million, or $2.71 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gossamer Bio, Inc. reported the three months ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022, was $55.8 million, EPS $0.59 per share.

Period: the three months ended December 31, 2022
Net income: Net loss for the three months ended December 31, 2022, was $55.8 million
EPS: $0.59 per share
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2022, was $55.8 million, or $0.59 per share

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.